Imaging Central Nicotinic Acetylcholine Receptors in Baboons with \([^{18}F]\)Fluoro-A-85380

Héric Valette, Michel Bottlaender, Frédéric Dollé, Ilonka Guenther, Chantal Fuseau, Christine Coulon, Michele Ottaviani and Christian Crouzel

Service Hospitalier Frédéric Joliot, Département de Recherche Médicale, Commissariat à l’Energie Atomique, Orsay, France

Central nicotinic acetylcholine receptors (nAChRs) have been implicated in learning-memory processes. Postmortem brain tissue of patients who suffered senile dementia or Parkinson’s disease shows low density of nAChRs. In this study, we used PET to evaluate the distribution and kinetics of the fluoro derivative of the high-affinity and \(\alpha_4\beta_2\)-subtype-selective, nicotinic ligand \(3-[2(S)-2\text{-azetidinylmethoxy}]\)pyridine (A-85380) in baboons. **Methods:** After intravenous injection of 37 MBq (1 mCi, 1.1–1.5 nmol) \([^{18}F]\)fluoro-A-85380 into isoflurane-anesthetized baboons, dynamic PET data were acquired for 180 min. Time-activity curves were generated from regions of interest. Displacement experiments (80 min after injection of the radiotracer) were performed using cytisine (1 mg/kg subcutaneously) and unlabeled fluoro-A-85380 (0.1 and 0.3 mg/kg intravenously). Toxicological studies were performed in mice. **Results:** Brain radioactivity reached a plateau within 40–50 min of injection of the tracer. In the thalamic area, radioactivity remained constant for 180 min, while clearance from the cerebellum was slow (t1/2 = 145–190 min). Cytisine and unlabeled fluoro-A-85380 reduced brain radioactivity at 180 min by 50%–60%, 30%–35% and 20%–35% of control values in the thalamus, cerebellum and frontal cortex, respectively. A slight, transient increase (20 mm Hg) in blood pressure was observed with the highest displacing dose of unlabeled fluoro-A-85380. Lethal dose in mice was found to be 2.2 mg/kg intravenously. **Conclusion:** These results demonstrate the feasibility and the safety of imaging nAChRs in vivo using labeled or unlabeled fluoro-A-85380.

**Key Words:** brain; nicotinic receptors; nonhuman primates; PET; \(3-[2(S)-2\text{-azetidinylmethoxy}]\)pyridine; \([^{18}F]\)fluorine

**J Nucl Med 1999; 40:**1374–1380

Nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout the central and the peripheral nervous system, where they modulate several central nervous system functions including neurotransmitter release, cognitive function, anxiety, analgesia and control of cerebral blood flow. In the brain, a major subtype is composed of the \(\alpha_4\beta_2\) subunit combination. Density of this subtype has been shown to be decreased in patients with neurodegenerative disease, such as Alzheimer’s disease and Parkinson’s disease (1), schizophrenia and epilepsy (2). To study in vivo with PET the evolution of Alzheimer’s and Parkinson’s disease and the changes in the neuronal biochemistry induced by therapeutic agents, several nicotinic PET ligands have been developed. \([^{11}C]\)nicotine was the first (3,4), but its use is hampered by problems such as nonspecific binding and blood flow dependency (5,6). Compounds chemically related to nicotine (such as \([^{11}C]\) Abbott Laboratories (ABT)-418 [7]) or to cytisine (such as \([^{11}C]\)methylcytisine [7]) were shown to be unsuitable for PET studies of nAChRs. ABT-418 interacted with the central nAChRs for only a short period, whereas methylcytisine did not cross the blood-brain barrier. 3-[1-\([^{14}C]\)methyl-2(S)-pyrrolidinyl)methoxy]pyridine (14C)A-85453) (8) seems to be more promising, but only data in mice are available. The most potent ligand has been epibatidine, which has a 40- to 50-pmol/L affinity for central nAChRs (9). It has been successfully labeled with \(^{18}F\) (10,11) and \(^{75}Br\) (12). The addition of a halogen atom to the parent compound did not change the affinity for nAChRs (10,12). Brain kinetics were studied in rodents and baboons. The higher uptake of the ligand was observed in the thalamus, with a thalamus-to-cerebellum radioactivity ratio of approximately 4–7 for the fluorinated and brominated ligands, respectively, 2–3 h after injection (10,12). But the use of epibatidine and \([^{18}F]\)fluoro-epibatidine creates theoretical (two nicotinic binding sites with different affinity) as well as practical (toxicity) problems (13–16).

A series of nAChR ligands with high affinity has been reported (17). Among them, 3-[2(S)-2-azetidinylmethoxy]-pyridine (A-85380) showed affinity for nAChRs similar to that of epibatidine. Both compounds competitively displace \([^{3}H]\)cytisine in a concentration-dependent manner with \(K_I\) values of 43 and 52 pmol/L for epibatidine and A-85380, respectively (Table 1) (18). \([^{3}H]\)A-85380 binds with high affinity to nAChRs (\(K_d = 50 \text{pmol/L}\)), and specific binding represented 80%–90% of total binding. In vitro kinetic analysis of \([^{3}H]\)A-85380 binding at 37°C revealed association and dissociation half-times favorable for in vivo studies (2.5 and 15.1 min, respectively) (19). A-85380 has an efficacy similar to epibatidine for stimulating \(^{86}Rb^+\) flux in human \(\alpha_4\beta_2\) K177 cells (7). The action of A-85380 at \(\alpha_4\beta_2\) was 100-fold lower than that of epibatidine. Furthermore,
2-fluoro-A-85380 is less toxic than fluoro-epibatidine (lethal dose \([LD_{50}] = 7 \mu\text{mol/kg} \) intravenously in mice and \([LD_{30}] = 0.5 \text{nmol/kg} \) intravenously in rats \([16,20]\)). \([^{18}\text{F}]\)fluoro-A-85380 has been shown to bind with high affinity to nAChRs in vitro (competitive displacement of \([^{3}H]\) epibatidine in a concentration-dependent manner with a \(K_I\) value = 80 pmol/L; RF Dannals, personal communication, April 1998). Furthermore, studies in mice showed high thalamic uptake with a thalamus-to-cerebellum ratio of 20, 180 min after injection of the tracer \([20]\). Such pharmacological properties led us to label A-85380 with \(^{18}\text{F}\), as done recently by another PET center \([21]\), and to study in vivo the characteristics of the tracer in the mouse and baboon brains.

### MATERIALS AND METHODS

#### Radiosynthesis of \([^{18}\text{F}]\)fluoro-A-85380

\([^{18}\text{F}]\)fluoro-A-85380 has been radiolabeled with no-carrier-added \(^{18}\text{F}\) by nuclophilic aromatic nitro-to-fluoro substitution using \([^{18}\text{F}]\)KF in dimethyl sulfoxide by conventional heating at 150°C for 20 min or by microwave activation at 100 W for 1 min \([22]\). In less than 2 h, 4.1–5.2 GBq (110–140 mCi) \([^{18}\text{F}]\)fluoro-A-85380 could be obtained with specific radioactivities of 111–185 GBq/\(\mu\text{mol}\) (3–5 Ci/\(\mu\text{mol}\)) calculated for end of bombardment (EOB). Yields (with respect to \(^{18}\text{F}\) ion): decay corrected 49%–64%. Total synthesis time from EOB: 105–110 min. High-performance liquid chromatography (HPLC)-purified product was found by HPLC analysis to be >98% chemically and radiocromically pure. It was also shown to be radiochemically stable for at least 180 min in physiological saline. Labeling precursor (2-nitro-3-\((\text{S})-\text{N-(tert-butoxycarbonyl)}\)-2-azetidinylmethoxy]pyridine) and authentic, unlabeled fluoro-A-85380 were prepared as follows. Briefly, Mitsunobu coupling of (\((\text{S})-\text{N-(tert-butoxycarbonyl)}\)-2-azetidinylmethanol and 3-hydroxy-2-nitropyridine or 2-fluoro-3-hydroxy pyrididine, using diethyl azodicarboxylate and triphenylphosphine in tetrahydrofuran at room temperature, gave 2-nitro-3-\((\text{S})-\text{N-(tert-butoxycarbonyl)}\)-2-azetidinylmethoxy]pyridine (the labeling precursor) and 2-fluoro-3-\((\text{S})-\text{N-(tert-butoxycarbonyl)}\)-2-azetidinylmethoxy]pyridine in 40% and 42% yield, respectively. Trifluoroacetic acid removal of the tert-butoxycarbonyl function gave fluoro-A-85380 in 96% yield.

### Animal Studies

Animal use procedures were in accordance with the recommendations of the European Economic Community \((86/609/\text{CEE})\) and the French National Committee \((\text{decret 87/848})\) for the care and use of laboratory animals.

#### Studies in Mice

Male Swiss mice weighing 20 g were used in experiments. For kinetics studies, each animal received 0.37 MBq \((10 \mu\text{Ci})\) \([^{18}\text{F}]\)fluoro-A-85380 dissolved in 0.1 mL saline by injection in a tail vein. At designated times \((n = 5 \text{ mice at } 15, 30, 90 \text{ and } 180 \text{ min})\) after injection of the radiotracer, animals were killed by decapitation, the brains were quickly removed, dissected, weighed and assayed for regional radioactivity. Pretreatment with cytisine (5 mg/kg subcutaneous) or with unlabeled fluoro-A-85380 (0.5 mg/kg intravenously) administered 30 min before injection of the radiotracer was performed. Animals were killed 120 min after injection of the tracer.

A coarse assessment of the acute intravenous toxicity of fluoro-A-85380 was performed in mice. A first dose of 0.275 mg/kg was injected through a tail vein in 10 animals. The injected dose was increased by a factor of two for the next group of 10 animals and so on until the death of all animals receiving the last dose.

#### PET Studies in Baboons

PET studies of the brain distribution of \([^{18}\text{F}]\)fluoro-A-85380 were performed in adult (mean weight 10 kg) Papi no papio baboons. Two hours before the PET acquisition the animals received ketamine (10 mg/kg intramuscularly). After being intubated, animals were artificially ventilated and anesthetized with 66% \(\text{N}_2\text{O}/1\%\) isofluorane (Ohmeda ventilator OAV 7710; Ohmeda, Madison, WI). PET experiments were performed with an HR-Exact positron tomograph (CTI PET Systems, Knoxville, TN). This scanner allowed simultaneous acquisition of 63 slices every 2.2 mm with spatial and axial resolutions of 4.5 mm. Transmission scans were acquired for 15 min using three retractable \(^{64}\text{Ge}\) rod sources. The baboon's head was positioned in the tomograph using a custom-designed stereotactic headholder. All the cerebral regions studied (cortex, diencephalon, cerebellum) were contained in axial cross sections parallel to the orbitomeatal anatomic line of reference \([23]\). Baboons \((n = 3)\) were injected intravenously with 37 MBq (1 mCi, 1–1.5 nmol) \([^{18}\text{F}]\)fluoro-A-85380 and imaged for 180 min. The scanning protocol consisted of 33 images \((6 \times 1 \text{ mm}, 7 \times 2 \text{ min}, 8 \times 5 \text{ min}, 12 \times 10 \text{ min})\) for a total duration of 3 h. During PET acquisition, arterial blood samples were withdrawn from the femoral artery at designated times. We examined whether the \([^{18}\text{F}]\)fluoro-A-85380 cerebral uptake could be displaced by injecting cytisine (1 mg/kg subcutaneously, \(n = 1)\) or unlabeled fluoro-A-85380 \((0.1 \text{ or } 0.3 \text{ mg/kg intravenously, } n = 1)\) for each dose) 80 min after the radiotracer injection. PET imaging was continued for 100 min with the scanning protocol mentioned above. Heart rate and blood pressure (femoral artery) were continuously monitored during the displacement experiments using unlabeled fluoro-A-85380. A precipitation experiment \((n = 1)\) was performed using a dose of 0.2 mg/kg unlabeled fluoro-A-85380 injected as a slow bolus \((10 \text{ min})\) 1 h before injection of the radiotracer. This PET experiment lasted 180 min. For PET data analysis, regions of interests were delineated on images on which anatomic structures (frontal cortex, thalamus, cerebellum) could be clearly identified. The concentration of radioactivity in each region of interest was determined during each sequential scan and expressed as percentage of the injected dose per milliliter \((%\text{ID/mL})\) of tissue. Percentage changes in thalamic and cerebellar radioactivities were calculated at the end of the PET experiment \((180 \text{ min})\) by dividing the difference in radioactivity (control experiment – challenge experiment) by the value of the radioactivity in the control experiment at 180 min.

#### TABLE 1

<table>
<thead>
<tr>
<th>nAChR</th>
<th>A-85380</th>
<th>Epibatidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(K_{\alpha}^{48})</td>
<td>52 pmol/L</td>
<td>43 pmol/L</td>
</tr>
<tr>
<td>(K_{\alpha}^{7})</td>
<td>148 nmol/L</td>
<td>16 nmol/L</td>
</tr>
<tr>
<td>(K_{\alpha}^{38})</td>
<td>0.7 (\mu)mol/L</td>
<td>0.007 (\mu)mol/L</td>
</tr>
<tr>
<td>(K_{\alpha}^{18})</td>
<td>310 nmol/L</td>
<td>2 nmol/L</td>
</tr>
<tr>
<td>(K_{\alpha}^{18y})</td>
<td>50 pmol/L</td>
<td>50 pmol/L</td>
</tr>
</tbody>
</table>

Data from reference 18.
Determination of Metabolites In Baboons

For analysis of metabolites, arterial blood samples (3 mL) were collected at 1, 2, 5, 11, 19, 27.5, 42.5 and 65 min after injection of the tracer and immediately centrifuged (5 min, 2000g, at 4°C) to obtain cell-free plasma. For deproteinization, 0.5 mL plasma was mixed with 0.7 mL acetonitrile containing fluoro-A-85350 (0.05 mg/mL) as reference compound. After centrifugation at 2000g for 5 min the supernatant (approximately 1.1 mL) was transferred into 1.5-mL microtubes. Acetonitrile was evaporated under reduced pressure using a vacuum centrifuge (Speed vac SVC 1004—220; Bioblock, Illkirch, France, 20—30 min, vacuum 0.01 bar). The remaining samples of 450—500 µL were directly used for HPLC analysis. The HPLC system consisted of two LC-10AS pumps (Shimadzu, Kyoto, Japan), a 2.6-mL mixing chamber, a Valco injector (model C6W; Valco, Schenkon, Switzerland) with a 1-mL loop and a reverse-phase Waters µ Bondapak C18 column (300 × 7.8 mm, 10 µm; Waters, Milford, MA) connected to an ultraviolet detector (Shimadzu SPD-10A; Shimadzu) operated at 254 nm followed by a radioisotope detector (model LB 506; Berthold, Wildbad, Germany, 500-µL cell). A Berthold LB 5035 pump was used to add liquid scintillator to the eluent just before the radioactivity detector. The data acquisition and handling were performed on a personal computer with the software Winflow (version 1.21; JMBS Developpements, Grenoble, France). The column was eluted applying a gradient from 5% acetonitrile in 0.01 mol/L phosphoric acid increasing to 35% in 7.5 min, increasing to 50% acetonitrile in 9.5 min, decreasing to 5% acetonitrile at 9.6 min with a total run length of 12 min. The flow rate of the eluent as well as the flow rate of the liquid scintillator was maintained at 6 mL/min.

RESULTS

Studies in Mice

Thalamic uptake of radioactivity peaked at 30 min (5.97 %ID/g) with a thalamus-to-cerebellum ratio of 1.7. Radioac-
Radioactivity in these two structures decreased rapidly (Fig. 1), but the thalamus-to-cerebellum radioactivity ratio increased with time (13.7 at 180 min). Pretreatment with cytisine reduced both thalamic and cerebellar radioactivities by 85% and 46%, respectively (Fig. 2). Pretreatment with unlabeled fluoro-A-85380 reduced both thalamic and cerebellar radioactivities by 76% and 39%, respectively.

LD100 was found to be 2.2 mg/kg. At 1.65 mg/kg, all animals had seizures but none died. The maximal dose without any clinical side effect was 1.5 mg/kg.

PET Data in Baboons

Kinetics of the tracer in cerebral structures and in plasma (uncorrected for metabolites) are shown (Fig. 3). Highest radioactivity was found in the thalamus and plateaued from 40 to 180 min with a maximal value of 3.73 ± 0.2 %ID/100 mL tissue (n = 8). Two baboons underwent four PET examinations each. In the first one, thalamic uptake (80 min postinjection) was 3.81 ± 0.15 %ID/100 mL (range 3.61–3.98 %ID/100 mL). In the second one, the corresponding values (at the same time) were 3.52 ± 0.22 %ID/100 mL (range 3.2–3.72 %ID/100 mL). Peak radioactivity in the cerebellum was 2.67 ± 0.13 %ID/100 mL tissue (n = 8). Clearance from cerebellum was slow (t1/2 = 2.5–3 h). The thalamus-to-cerebellum radioactivity ratio increased slightly with time: 1.8 ± 0.07 at 80 min and 2.1 ± 0.06 at 180 min (n = 2). Injection of cytisine (Fig. 4) displaced 52% of thalamic radioactivity, whereas 23% of cerebellar radioactivity was displaced at 180 min postinjection (data obtained in the same baboon in two separate experiments) (Table 2). Injection of unlabeled fluoro-A-85380 (Fig. 5) (0.1 or 0.3 mg/kg intravenously, n = 1 for each dose) displaced thalamic radioactivity by 53% and 63% at 180 min postinjec-


FIGURE 4. Displacement by cytisine (1 mg/kg subcutaneously) injected at 80 min. ■ = thalamus; ● = cerebellum.
TABLE 2
Percentage Changes at 180 Min in Selected Baboon Cerebral Structures Induced by Administration of Fluoro-A-85380 and Cytisine During PET Experiments

<table>
<thead>
<tr>
<th>Structure</th>
<th>Displacement by fluoro-A-85380 0.1 mg/kg</th>
<th>Displacement by fluoro-A-85380 0.3 mg/kg</th>
<th>Displacement by cytisine 1 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalamus</td>
<td>53%</td>
<td>63%</td>
<td>52%</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>26%</td>
<td>31%</td>
<td>23%</td>
</tr>
<tr>
<td>Frontal cortex</td>
<td>20%</td>
<td>35%</td>
<td>22%</td>
</tr>
</tbody>
</table>

DISCUSSION

In this study, the kinetics and regional brain distribution of a fluorinated analog of A-85380 were assessed using PET in baboons. This compound is likely to be a nicotinic ligand because, in mice, presaturation with cytisine strongly decrease thalamic uptake. A similar decrease (88%) (20) in the thalamic radioactivity was found in CD-1 mice after the administration of the same amount of cytisine. Although the cerebellum is an mAChR-poor area, specific binding was demonstrated in vivo in this structure for nicotine (7). In this study, a reduction (46%) of cerebellar uptake after pretreatment with cytisine was observed; a similar value (40%) was reported in CD-1 mice using the same dose of cytisine (RF Dannals, personal communication, November 1998). This fact differentiates fluoro-A-85380 from fluoro-epibatidine (10).

Presaturation experiments by unlabeled fluoro-A-85380 showed a residual binding in the thalamus of 25%. In this cerebral structure, the corresponding value in baboons is 30%. In the cerebellum, uptake of the radiotracer was reduced by only 40%, suggesting a higher nonspecific binding than that observed with fluoro-epibatidine (24). We could use unlabeled fluoro-A-85380 for displacement and presaturation experiments because its acute intravenous toxicity in mice appeared to be clearly lower than that of other nicotinic PET ligands. The first dose we used in baboons was chosen as one tenth of the higher dose, which did not produce a clinical side effect in mice. Using this dose, no clinical or hemodynamic effect was observed in
baboons. When the dose was increased three-fold, only a slight transient increase in blood pressure was observed. Therefore, the use of fluoro-A-85380 appears to be relatively safe in anesthetized nonhuman primates. The metabolism of fluoro-A-85380 is rather slow, but the three lipophilic metabolites (chemically unknown) detected in plasma could cross the blood-brain barrier and therefore could contribute to nonspecific binding.

Brain kinetics of $[^{18}F]$fluoro-A-85380 are strikingly different in mice and baboons. Although there are species differences in the distribution of central nAChRs in mammalian brain (25,26), the effects of anesthesia cannot be ruled out. Volatile, halogenated anesthetic agents have been shown to stabilize the slow desensitized conformational state of nAChRs, an inactive state characterized by high affinity for agonists (27,28). The α4β2 nAChRs are especially affected by isoflurane, the anesthetic agent used in this study. The changes in nAChR affinity induced by isoflurane can also explain the difference in the shape of thalamic time-activity curves. In nAChR-rich areas in anesthetized baboons, the kinetics of $[^{18}F]$fluoro-A-85380 are slow, a possible drawback for clinical use (if the brain kinetics of the tracer are similar in humans). Two injections of the radiotracer are usually performed for quantification of receptors. The second injection is performed when equilibrium is reached. For fluoro-A-85380, this equilibrium is reached in baboons at 100–140 min. Such slow kinetics suppose a PET acquisition lasting at least 200 min, which seems long for patients with senile dementia.

In vitro studies have shown that A-85380 competitively displaced $[^{3}H]$cytisine from α4β2 nAChR subtype in a concentration-dependent manner consistent with a single site competitive model with $K_i$ values of 52 pmoL (18). $[^{18}F]$fluoro-A-85380 binding to nAChRs also exhibits pharmacological specificity. After administration of cytisine in vivo, a marked decrease in $[^{18}F]$fluoro-A-85380 binding was observed in nAChR-rich regions. This displacement was not observed in the eyes, where the nicotinic-bungarotoxin receptor subtype is abundant (29). Therefore, fluoro-A-85380 also showed a specific binding for α4β2 nAChRs.

The brain kinetics of $[^{18}F]$fluoro-A-85380 in isoflurane-anesthetized Papio papio is similar to that observed with $[^{18}F]$fluoroepibatidine (24) in Papio anubis anesthetized with alfaxalone acetate and alfadalone (steroid derivatives). These neurosteroids did not affect binding properties of $[^{3}H]$nicotine in vitro (30). In the study by Villemagne et al. (24), as in this study, a plateau was also observed in the thalamus (1.4 %ID/100 mL tissue) 40 min after injection of the tracer, whereas clearance ($t_{1/2}$) from the cerebellum was more rapid (approximately 3 h). A higher amount of radioactivity (67%) was displaced in the thalamus after injection of cytisine. In contrast, $[^{18}F]$fluoroepibatidine injected into isoflurane-anesthetized Papio anubis had completely different brain kinetics (11). Radioactivity (0.06 %ID/g) in the thalamus peaked 5–10 min after injection of the radiotracer. Clearance from the thalamus and the cerebel-

CONCLUSION

The results obtained in mice and baboons demonstrate the feasibility and relative safety of nAChRs in in vivo imaging using $[^{18}F]$fluoro-A-85380. Other studies to characterize this radiotracer are needed.

REFERENCES


FIGURE 6. Unchanged (●) fluoro-A-85380 and lipophilic metabolites (sum of three lipophilic metabolites, ▲) of fluoro-A-85380 within 80 min of injection of tracer. Data concerning hydrophilic metabolite are not shown because time-activity curve is almost superimposed to one of lipophilic metabolites. Values are mean ± SD (n = 1–4 baboons).


Imaging Central Nicotinic Acetylcholine Receptors in Baboons with [$^{18}$F]Fluoro-A-85380

Héric Valette, Michel Bottlaender, Frédéric Dollé, Ilonka Guenther, Chantal Fuseau, Christine Coulon, Michele Ottaviani and Christian Crouzel


This article and updated information are available at: [http://jnm.snmjournals.org/content/40/8/1374](http://jnm.snmjournals.org/content/40/8/1374)

Information about reproducing figures, tables, or other portions of this article can be found online at: [http://jnm.snmjournals.org/site/misc/permission.xhtml](http://jnm.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNM can be found at: [http://jnm.snmjournals.org/site/subscriptions/online.xhtml](http://jnm.snmjournals.org/site/subscriptions/online.xhtml)